A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906)
Cancer Research and Treatment · 2025
DOI: 10.4143/crt.2025.426 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Kwai Han Yoo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. Hauptthemen laut MEDLINE: Multiple Myeloma, Bortezomib, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Gachon University, Janssen Korea.
Abstract (Originalsprache)
PURPOSE: Daratumumab combined with bortezomib and dexamethasone (DVd) has been established as the standard treatment for relapsed/refractory multiple myeloma (MM) based on pivotal phase 3 trials. A subgroup analysis demonstrated enhanced efficacy in the second-line setting, although the fixed duration of bortezomib administration remained a limitation. Therefore, we conducted a phase II trial evaluating continuous bortezomib as maintenance in a DVd regimen for second-line treatment. MATERIALS AND METHODS: This phase II study (KCT0004352) enrolled patients with MM receiving second-line DVd therapy: daratumumab (16 mg/kg IV, weekly for cycles 1-3, every 3 weeks for cycles 4-8, every 4 weeks thereafter), bortezomib (1.3 mg/m2 subcutaneously, twice weekly for cycles 1-8, biweekly thereafter), and dexamethasone (20 mg IV or orally on treatment days), as in the pivotal trial. After nine cycles, daratumumab and bortezomib were continued until progression or unacceptable toxicity. The primary endpoint was a ≥ very good partial response (VGPR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety, and minimal residual disease (MRD) negativity assessed by EuroFlow-based next-generation flow in bone marrow. RESULTS: Between June 2020 and 2021, 26 patients (median age, 72 years) from 10 Korean centers were enrolled. All had one prior treatment line; 73% had prior bortezomib, and 69% had prior immunomodulators. At a median follow-up of 25.4 months, 65% discontinued due to progression, death, or withdrawal. VGPR or better was achieved in 65%, with 23% MRD-negative. Median PFS was 21.8 months; OS was not reached. The 24-month OS rate was 69.2%. Grade 3 adverse events included thrombocytopenia and lymphopenia; 31% had serious adverse events, and 65% required dose modifications. CONCLUSION: Continuous DVd therapy showed promising efficacy and manageable toxicity as a second-line option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
- Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Division of Hematology and Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea.
- Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
- Division of Hematology/Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Förderung
- Gachon University
- Janssen Korea
Zitieren
APA
Yoo, K. H., Yoon, S. E., Kang, K. W., Yi, J. H., Kim, M. K., Kim, H. J., Kim, S. H., Park, J. S., Jung, S. H., Lee, J. J., Min, C. K., Lee, J. H., Cho, D., & Kim, K. (2025). A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906). Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.426
Vancouver
Yoo KH, Yoon SE, Kang KW, Yi JH, Kim MK, Kim HJ, et al. A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906). Cancer Research and Treatment. 2025. doi:10.4143/crt.2025.426
BibTeX
@article{Yoo2025,
author = {Yoo, Kwai Han and Yoon, Sang Eun and Kang, Ka-Won and Yi, Jun Ho and Kim, Min Kyoung and Kim, Hyo Jung and Kim, Sung-Hyun and Park, Joon Seong and Jung, Sung-Hoon and Lee, Je-Jung and Min, Chang-Ki and Lee, Jae Hoon and Cho, Duck and Kim, Kihyun},
title = {A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906)},
journal = {Cancer Research and Treatment},
year = {2025},
doi = {10.4143/crt.2025.426}
}
EUVIMED